SARS-CoV-2 virus is the cause of COVID-19 it was first detected in a cluster sample of patients in Hubei Province, China in December 2019. At first the cluster patient had symptoms such as a fever, cough, shortness of breath, and other non-specific symptoms. The aim of the study was to examine the positivity of nasal, nasopharyngeal and oropharynx specimens. The research subjects were contact patients with or without clinical symptoms of COVID-19 at the Health Service Facilities (Fasyankes) and the Department of Microbiology, FKUI. The data was collected by consecutive sampling specimens. Data analysis performed cross tabulation and calculation of sensitivity, specificity, PPV, and NPV. The study resulted in all contact patients aged over 18 years with or without clinical symptoms of COVID-19 who were tested at Health Service Facilities (Fasyankes) and the samples were sent to the Clinical Microbiology Laboratory (LMK) FKUI. Nasopharyngeal specimens were 34.84%, oropharyngeal specimens were 30.32%, and nasal specimens were 30.77%. The three types of specimens can be substituted for a molecular detection test as an initial diagnosis of COVID-19. RT-PCR on several types of specimens showed that nasal and oropharyngeal specimens could be used as an alternative to nasopharyngeal specimens.